Together, these findings suggest that manipulating the CK2/SPOP/PIAS1 axis to assist olaparib treatment could potentially create a “synthetic lethality,” offering improved outcomes for patients with PCa receiving olaparib treatment. The gene discussed is PIAS1; the disease is posterior cortical atrophy.